Chemours appoints Mary Cranston as board chair following leadership change

The Chemours Company (NYSE:CC), a $2.29 billion chemical manufacturing company, announced that its board of directors has appointed independent director Mary Cranston as chair of the board, effective September 2, 2025. Alister Cowan has been named lead independent director. These appointments follow the departure of Dawn Farrell, who has accepted a position with the Canadian government as chief executive officer of the newly created Major Projects Office under the Building Canada Act. According to InvestingPro data, the company operates with a significant debt burden, with a debt-to-equity ratio of 18.61, though maintains a healthy current ratio of 1.68.

The changes were disclosed in a press release statement included in a filing with the U.S. Securities and Exchange Commission.

Chemours, headquartered in Wilmington, Delaware, is listed on the New York Stock Exchange under the ticker symbol CC.

In other recent news, Chemours Company reported impressive financial results for the second quarter of 2025, with earnings per share reaching $0.58, surpassing analyst expectations of $0.46. The company’s revenue also exceeded forecasts, coming in at $1.62 billion against the anticipated $1.56 billion. Despite these strong results, Truist Securities maintained its Buy rating on Chemours, citing operational challenges in its Titanium Technologies and Advanced Performance Materials segments as reasons for a cautious outlook. In a strategic development, Chemours announced that Samsung Electronics has successfully qualified its Opteon two-phase immersion cooling fluid for use in current-generation solid-state drives, marking a significant milestone after nearly a year of testing. Additionally, Chemours is undergoing leadership changes, with Mary Cranston appointed as Chair of the Board and Alister Cowan as Lead Independent Director, following Dawn Farrell’s resignation to join the Canadian government. The company has acknowledged the importance of these leadership transitions and plans to make further announcements in due course. These developments reflect Chemours’ ongoing efforts to navigate operational challenges while capitalizing on new opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.